Are Peptides Legal in Rhode Island? (2026)

The federal rules that apply in Rhode Island, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in Rhode Island:

• Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
• Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including Rhode Island. The PCAC vote page has every tally.
• GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What Rhode Island law adds

Rhode Island's controlled-substances law (R.I. Gen. Laws Title 21, Chapter 21-28 (Uniform Controlled Substances Act); possession offences at § 21-28-4.01) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (web.archive.org)

The Bureau found no research peptide (BPC-157, TB-500, ipamorelin, sermorelin, semaglutide, tirzepatide, retatrutide or the others covered on this site) on Rhode Island's schedules or in a Rhode Island-specific ban as of September 2026. That is the position in most states.

Human growth hormone

Until 1 February 2025 Rhode Island's own Schedule III expressly listed human growth hormone and chorionic gonadotropin alongside anabolic steroids, which went beyond federal law. That section was repealed (P.L. 2024 ch. 390 and 391) and the Department of Health wrote in April 2026 that it defers to the federal schedules, so HGH and hCG are no longer state-scheduled and only the federal HGH statute applies. The repeal rests on a statute listing and the department's letter; the post-repeal schedule mechanism should be confirmed. (Former R.I. Gen. Laws § 21-28-2.08, Schedule III(d), repealed effective 1 February 2025; Department of Health letter on S 2889, April 2026) (web.archive.org)

Compounded semaglutide and tirzepatide

No Rhode Island Board of Pharmacy statement specific to compounded GLP-1 drugs was located. Licensed Rhode Island pharmacies follow the federal 503A and 503B rules, under which the shortage exception for semaglutide and tirzepatide has ended.

Clinics, medspas and prescribers

No Rhode Island medical board guidance specific to peptide therapy was located. A Rhode Island prescriber who administers BPC-157 or another unapproved peptide is exposed under the state's medical practice act and, since the FDA's 2026 letters, under federal law; the July 2026 advisory vote has not changed that yet.

Buying, possessing and using research peptides in Rhode Island

Rhode Island has no offence for possessing a research peptide that is not a scheduled controlled substance; § 21-28-4.01(c)(1) makes it unlawful to knowingly possess a controlled substance without a valid prescription, and no general offence for possessing a non-controlled prescription drug was found. (web.archive.org)

Ordering from a vendor in another state. Almost every research-peptide order into Rhode Island is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Yes. Board of Medical Licensure rule 216-RICR-40-05-1 § 1.5.9(H) holds telemedicine prescribing to the in-person standard and says treatment, including a prescription, based solely on an online questionnaire without an appropriate evaluation is not an acceptable standard of care and is unprofessional conduct; no in-person examination is required for non-controlled drugs such as semaglutide. (law.cornell.edu) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a Rhode Island law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Enforcement in Rhode Island

• 2025-02-19. Attorney General Peter Neronha signed the 38-state letter urging the FDA to act against counterfeit GLP-1s and online sellers of research-purposes-only semaglutide and tirzepatide. (tn.gov)

A warning letter, lawsuit or board complaint is an allegation by the body that issued it, not a court finding, unless the entry says otherwise.

Editor's note. The state legislature and health department sites were unreachable during this check, so the statute text comes from archived captures. No Board of Pharmacy or Board of Medical Licensure statement on compounded GLP-1s or peptides was found.

Frequently asked questions

Is BPC-157 legal in Rhode Island?

Rhode Island has not scheduled BPC-157, so possessing it is not a Rhode Island offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in Rhode Island?

Yes. Board of Medical Licensure rule 216-RICR-40-05-1 § 1.5.9(H) holds telemedicine prescribing to the in-person standard and says treatment, including a prescription, based solely on an online questionnaire without an appropriate evaluation is not an acceptable standard of care and is unprofessional conduct; no in-person examination is required for non-controlled drugs such as semaglutide. Compounded versions are no longer covered by the FDA's shortage exception, and the FDA has proposed keeping semaglutide and tirzepatide off the 503B bulks list, so expect availability of compounded product to keep shrinking.

Is HGH legal in Rhode Island?

Only with a valid prescription for an approved use. Rhode Island does not schedule it separately, but federal law, 21 U.S.C. section 333(e), makes distribution or possession for any non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

• https://web.archive.org/web/20241122001720id_/http://webserver.rilin.state.ri.us/Statutes/TITLE21/21-28/21-28-4.01.HTM
• https://web.archive.org/web/20240412175456id_/http://webserver.rilin.state.ri.us/Statutes/TITLE21/21-28/21-28-2.08.htm
• https://www.law.cornell.edu/regulations/rhode-island/216-RICR-40-05-1.5
• https://www.tn.gov/content/dam/tn/attorneygeneral/documents/pr/2025/2025-2-glp1-letter.pdf

Every Rhode Island fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.